The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.
from Cancer via ola Kala on Inoreader http://ift.tt/2xc6NLA
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου